Trials / No Longer Available
No Longer AvailableNCT00511771
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 18 Years – 54 Years
- Healthy volunteers
- —
Summary
To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod | Tegaserod maleate |
Timeline
- First posted
- 2007-08-06
- Last updated
- 2010-11-18
Source: ClinicalTrials.gov record NCT00511771. Inclusion in this directory is not an endorsement.